Login to Your Account



Clinic Roundup


Friday, June 21, 2013

Pharmacyclics Inc., of Sunnyvale, Calif., said the New England Journal of Medicine online published results of a Phase II study evaluating the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, in patients with relapsed/refractory mantle cell lymphoma (MCL). The data suggest ibrutinib may be effective and generally well tolerated in patients with relapsed/refractory MCL.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription